Climb Bio Inc (CLYM) Stock Price, Quote & News

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 857 2596

Website: climbbio.com

Address:

20 William Street, Suite 145, Wellesley Hills, United States

StockScanners Aug. 23 at 7:08 PM

$CLYM reached 2.42

1 · Reply

BigWins3 Aug. 23 at 11:17 AM

$CLYM This is my Grandpa Palphie, he pays for a stocktwits monthly membership and pretends he has lots of money, rest assured grandma left him because he was caught wearing her under garmets and playing dress up. I hate to air out our family's dirty laundry but he was wearing it so I have no choice.

0 · Reply

SpectreStrat Aug. 23 at 9:24 AM

$CLYM The Calamos Dynamic Convertible and Income Fund is a leveraged closed-end convertible fund

0 · Reply

Ralphbeach Aug. 23 at 1:18 AM

BIGwins...$CLYM take your lunch money and buy some. With your gains enroll in charm school. Peace ✌️ out

1 · Reply

cheating_stock_investor Aug. 22 at 2:14 PM

$CLYM very quiet board yet slow accumulation increase in stock price. Tells you this is the place to be with no noise

0 · Reply

StockScanners Aug. 21 at 12:32 AM

$CLYM keep watch if this holds above 2.10

0 · Reply

Chumpchange53 Aug. 20 at 9:30 PM

$CLYM Wash ,rinse, repeat kind of day

0 · Reply

cheating_stock_investor Aug. 20 at 7:01 PM

$CLYM is kt still active?

0 · Reply

macd87 Aug. 20 at 2:07 PM

$CLYM what is going on, how come no volume in the middle of the week

0 · Reply

Chumpchange53 Aug. 18 at 8:35 PM

$CLYM BOOOOYAAAAAAA!!!!

0 · Reply

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

May 19, 2025, 4:34 PM EDT - 3 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 7:00 AM EDT - 3 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Mar 27, 2025, 7:00 AM EDT - 5 months ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 5 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Feb 25, 2025, 7:00 AM EST - 6 months ago

Climb Bio to Present at Upcoming Investor Conferences

Feb 24, 2025, 7:00 AM EST - 6 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 4, 2025, 7:00 AM EST - 7 months ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 7:00 AM EST - 8 months ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Dec 19, 2024, 7:00 AM EST - 8 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Nov 12, 2024, 4:05 PM EST - 10 months ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 11, 2024, 7:00 AM EST - 10 months ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Oct 15, 2024, 7:00 AM EDT - 11 months ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 11, 2024, 12:30 PM EDT - 11 months ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 4, 2024, 7:00 AM EDT - 11 months ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 3, 2024, 10:00 AM EDT - 11 months ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 2, 2024, 9:00 AM EDT - 11 months ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Jun 28, 2024, 1:58 PM EDT - 1 year ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Jul 20, 2023, 6:57 AM EDT - 2 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:45 AM EDT - 2 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

May 11, 2023, 4:10 PM EDT - 2 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 2 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Feb 9, 2023, 4:01 PM EST - 2 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Nov 30, 2022, 7:00 AM EST - 2 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Aug 15, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 2, 2022, 9:33 AM EDT - 3 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Jul 7, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Jun 27, 2022, 4:01 PM EDT - 3 years ago

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Jun 21, 2022, 12:01 PM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

TXMD WEBR

Jun 13, 2022, 10:49 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

TXMD BEEM

May 16, 2022, 11:38 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

CWH VERU

May 16, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

Apr 25, 2022, 1:45 PM EDT - 3 years ago

Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic

Apr 25, 2022, 9:06 AM EDT - 3 years ago

See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting

StockScanners Aug. 23 at 7:08 PM

$CLYM reached 2.42

1 · Reply

BigWins3 Aug. 23 at 11:17 AM

0 · Reply

SpectreStrat Aug. 23 at 9:24 AM

$CLYM The Calamos Dynamic Convertible and Income Fund is a leveraged closed-end convertible fund

0 · Reply

Ralphbeach Aug. 23 at 1:18 AM

BIGwins...$CLYM take your lunch money and buy some. With your gains enroll in charm school. Peace ✌️ out

1 · Reply

cheating_stock_investor Aug. 22 at 2:14 PM

$CLYM very quiet board yet slow accumulation increase in stock price. Tells you this is the place to be with no noise

0 · Reply

StockScanners Aug. 21 at 12:32 AM

$CLYM keep watch if this holds above 2.10

0 · Reply

Chumpchange53 Aug. 20 at 9:30 PM

$CLYM Wash ,rinse, repeat kind of day

0 · Reply

cheating_stock_investor Aug. 20 at 7:01 PM

$CLYM is kt still active?

0 · Reply

macd87 Aug. 20 at 2:07 PM

$CLYM what is going on, how come no volume in the middle of the week

0 · Reply

Chumpchange53 Aug. 18 at 8:35 PM

$CLYM BOOOOYAAAAAAA!!!!

0 · Reply

Nfjkdjndnd Aug. 18 at 4:20 PM

$CLYM if this stays sideways around $2, I’ll be watching for a straight line up to $2.20+ at some point today

0 · Reply

vu_jade Aug. 18 at 2:36 PM

$CLYM as in Climb!

0 · Reply

cheating_stock_investor Aug. 18 at 2:23 PM

$CLYM creeping up sleeper stock ready to trade above cash value with a little good news. Friend of mine gave this to me not too long ago with 6 dollar pt.

0 · Reply

kaefer Aug. 16 at 8:21 AM

$CLYM Nice setup!

0 · Reply

vu_jade Aug. 15 at 4:57 PM

$CLYM climbing

0 · Reply

kshonstocks Aug. 15 at 3:32 PM

$CLYM Climb Bio initiated with an Outperform at Baird on budoprutug potential 09:06 CLYM As previously reported, Baird initiated coverage of Climb Bio with an Outperform rating and $9 price target per the fly

0 · Reply

kshonstocks Aug. 15 at 3:24 PM

$CLYM is 200 dma b/o

0 · Reply

JarvisFlow Aug. 15 at 2:19 PM

Baird has adjusted their stance on Climb Bio ( $CLYM ), setting the rating to Outperform with a target price of 9.

0 · Reply

Fakhrul123 Aug. 14 at 8:12 PM

$CLYM According to Wall Street analysts, ClimbBio (CLYM) stock is expected to rise over the next 12 months. The average 1-year price target is around $9.00 to $10.20, with a high of $10.50 and a low of $7.00. Analysts have given the stock a consensus rating of "Buy".

0 · Reply

Fakhrul123 Aug. 14 at 8:11 PM

$CLYM hey! Prediction is $5 by September

0 · Reply

Hugoooo Aug. 14 at 1:06 PM

$CLYM can’t believe it is so quiet here

0 · Reply

Fakhrul123 Aug. 14 at 12:35 PM

$CLYM

0 · Reply

Market Cap	148.40M
Revenue (ttm)	0.00
Net Income (ttm)	-73.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	803,800
Avg Vol	511,864
Day's Range	N/A - N/A
Shares Out	67.76M
Stochastic %K	95%
Beta	-0.11
Analysts	Strong Sell
Price Target	$9.00